Health & Fitness
Wed, May 25, 2011Tue, May 24, 2011Mon, May 23, 2011Sun, May 22, 2011Fri, May 20, 2011Thu, May 19, 2011Wed, May 18, 2011Tue, May 17, 2011Mon, May 16, 2011Sun, May 15, 2011Fri, May 13, 2011Thu, May 12, 2011Wed, May 11, 2011Tue, May 10, 2011Mon, May 9, 2011Sun, May 8, 2011Sat, May 7, 2011Fri, May 6, 2011Thu, May 5, 2011Wed, May 4, 2011Tue, May 3, 2011Mon, May 2, 2011Fri, April 29, 2011Thu, April 28, 2011Wed, April 27, 2011Verastem, Inc. Appoints Robert Forrester as Chief Operating Officer
//health-fitness.news-articles.net/content/2011/ .. robert-forrester-as-chief-operating-officer.html
Published in Health and Fitness on Thursday, May 12th 2011 at 10:35 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
BOSTON--([ BUSINESS WIRE ])--Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and othercancers by targeting cancer stem cells, today announced the appointment of Robert Forrester, LL.B., as Chief Operating Officer.
"Verastem is committed to bringing the best science, resources and people together to develop the next generation of drugs designed to change the paradigm of cancer therapy."
Mr. Forrester joins Verastem with significant experience in developing life science companies. He has served as the CEO, COO, or CFO of private and public life science companies including Forma Therapeutics, CombinatoRx (NASDAQ: CRXX, now ZLCS) and Coley (NASDAQ: COLY, acquired by Pfizer).
aRobert has a tremendous record of success in attracting investment and managing life science companies,a said Ansbert Gadicke, M.D., Managing Director of MPM Capital and Verastem Board of Directors. aHe is one of the best business innovators in biotech and his expertise will be invaluable to Verastem.a
Previously, Mr. Forrester served as a managing director of the Proprietary Investment Group at MeesPierson, part of the Fortis Group, investing in life science companies. Prior to MeesPierson, Mr. Forrester worked in investment banking on M&A, public and private finance transactions at BZW (now Barclaya™s Capital) and UBS. He started his career as a lawyer with Clifford Chance in London and Singapore. Mr. Forrester holds a LL.B. from Bristol University and is a member of the Board of Directors of Myrexis Pharmaceuticals (NASDAQ: MYRX).
aThe addition of Robert Forrester to the Verastem team is a critical step forward,a said Christoph Westphal, M.D., Ph.D., Chairman of Verastem. aVerastem is committed to bringing the best science, resources and people together to develop the next generation of drugs designed to change the paradigm of cancer therapy.a
About Verastem, Inc.
Verastem, Inc. is a private biopharmaceutical company focused on discovering and developing drugs to treat breast and othercancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer.
Verastem was founded by Rich Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric Lander, Robert Weinberg and Christoph Westphal. Verastem is backed by Bessemer Venture Partners, Cardinal Partners, Longwood Founders Fund, and MPM Capital. For more information, please visit [ www.verastem.com ].
